Avalo Therapeutics, Inc. (AVTX) - Dilution Analysis

10-Q filing | 52.6M shares outstanding

10-K filing | 22.8M shares outstanding

S-3 filing: Avalo Therapeutics, Inc. files an S-3 registration statement to offer up to $750,000,000 of common stock, preferred stock, debt securities, warrants, and/or units from time to time.

10-Q filing | 18.1M shares outstanding

10-Q filing | 13.2M shares outstanding

8-K filing: Dr. Jain was granted a non-qualified stock option award to purchase 40,200 shares of the Company's common stock, vesting in three substantially equal installments, with an exercise price equal to the closing price of Avalo's common stock on June 17, 2025.

10-Q filing | 10.5M shares outstanding

10-K filing | 10.7M shares outstanding

10-Q filing | 10.8M shares outstanding

10-Q filing | 1.0M shares outstanding

S-3/A filing: This S-3/A filing relates to the resale or other disposition from time to time of (i) up to 22,357,897 shares of common stock issuable upon conversion of Series C non-voting convertible preferred stock, (ii) 22,357.897 shares of Series C non-voting convertible preferred stock, (iii) up to 11,967,526 shares of common stock issuable upon the exercise of warrants, and (iv) 11,967,526 warrants to purchase up to 11,967,526 shares of common stock (or 11,967.526 shares of Series C non-voting convertible preferred stock).

S-3/A filing: This S-3/A filing relates to the resale or other disposition from time to time of (i) up to 22,357,897 shares of our common stock issuable upon the conversion of shares of our Series C non-voting convertible preferred stock, (ii) 22,357.897 shares of our Series C non-voting convertible preferred stock, (iii) up to 11,967,526 shares of our common stock issuable upon the exercise of warrants, and (iv) 11,967,526 warrants to purchase up to 11,967,526 shares of our common stock held by the selling stockholders named in this prospectus.

S-3 filing: This S-3 filing relates to the resale or other disposition from time to time of (i) up to 22,357,897 shares of our common stock issuable upon the conversion of shares of our Series C non-voting convertible preferred stock, (ii) 22,357.897 shares of our Series C non-voting convertible preferred stock, (iii) up to 11,967,526 shares of our common stock issuable upon the exercise of warrants, and (iv) warrants to purchase up to 11,967,526 shares of our common stock (or 11,967.526 shares of Series C non-voting convertible preferred stock), all held by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors.

10-Q filing | 1.0M shares outstanding

10-K filing | 1.0M shares outstanding

8-K filing: Avalo Therapeutics, Inc. entered into a merger agreement with AlmataBio, Inc. and a securities purchase agreement for a private placement of Series C Preferred Stock and warrants, issuing 171,605 shares of common stock and 2,412 shares of Series C Preferred Stock to Almata stockholders, and agreeing to milestone payments, while also selling 19,945.890625 shares of Series C Preferred Stock to certain investors. ($115.6M proceeds)

8-K filing: Stock split 1-for-240 | Outstanding: 192,382,419 → 801,611

10-Q filing | 192.4M shares outstanding

8-K filing: The company sold 50,837,984 shares of common stock through Oppenheimer & Co. Inc. for net proceeds of approximately $12.9 million from May 4, 2023 through September 8, 2023, and subsequently sold 16,149,321 shares for net proceeds of approximately $1.8 million.

8-K filing: Avalo Therapeutics, Inc. entered into Amendment No. 1 to the Sales Agreement with Oppenheimer & Co. Inc. to increase the aggregate offering amount to $50,000,000, with approximately $41.7 million remaining available after previous sales. ($8.3M proceeds)

10-Q filing | 20.2M shares outstanding

8-K filing: Avalo Therapeutics, Inc. entered into an exchange agreement with entities affiliated with Venrock Healthcare Capital Partners, exchanging 1,300,000 shares of common stock for pre-funded warrants to purchase 1,300,000 shares of common stock.

10-Q filing | 13.2M shares outstanding

POS AM filing: This is a POS AM filing to remove unsold securities from a previous registration statement.

S-3 filing: The registrant is registering an indeterminate number of shares of common stock, preferred stock, debt securities, warrants and/or units with an aggregate initial offering price not to exceed $375,000,000.

10-K filing | 13.2M shares outstanding

8-K filing: Avalo Therapeutics, Inc. entered into an underwriting agreement for a public offering of 3,770,000 shares of common stock and warrants to purchase up to 3,770,000 shares of common stock, at a combined price of $3.98 per share and warrant, for gross proceeds of approximately $15 million. ($30.0M proceeds)

10-Q filing | 9.4M shares outstanding

10-Q filing | 9.4M shares outstanding

8-K filing: Stock split 1-for-12 | Outstanding: 112,794,203 → 9,405,724

10-Q filing | 112.8M shares outstanding

10-K filing | 112.8M shares outstanding

10-Q filing | 112.3M shares outstanding

8-K filing: Avalo Therapeutics, Inc. entered into an underwriting agreement for a public offering of 12,500,000 shares of common stock at $2.20 per share, with an option for the underwriters to purchase an additional 1,875,000 shares, expected to close on or about September 17, 2021. ($25.5M proceeds)

10-Q filing | 96.2M shares outstanding

8-K filing: Cerecor Inc. entered into a $35.0 million venture debt financing agreement with Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP, with $20.0 million funded on the Closing Date and the remaining $15.0 million fundable upon achieving certain milestones; additionally, the Company issued warrants to purchase 403,844 shares of common stock at an exercise price of $2.60.

10-Q filing | 88.6M shares outstanding

10-K filing | 89.1M shares outstanding

S-3 filing: The filing is an S-3 registration statement to register the offer and sale of common stock, preferred stock, warrants and/or debt securities.

8-K filing: Cerecor Inc. entered into an underwriting agreement for a public offering of 12,323,077 shares of common stock at $2.60 per share and pre-funded warrants to purchase 1,676,923 shares at $2.599 per warrant, with an option for the underwriters to purchase an additional 2,100,000 shares at $2.60 per share, expected to close on or about January 12, 2021. ($41.86M proceeds)

10-Q filing | 74.9M shares outstanding

10-Q filing | 74.9M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 1,951,219 shares of common stock by Armistice Capital Master Fund Ltd.

10-Q filing | 59.6M shares outstanding

10-K filing | 57.6M shares outstanding

8-K filing: Cerecor Inc. entered into a securities purchase agreement for the sale of 1,306,282 shares of common stock at $3.98 per share, with gross proceeds expected to be approximately $5.2 million. ($5.2M proceeds)